Business context and reporting period
Issuer identity: The request identifies Standard BioTools Inc., but the supplied 10-K is for Fluidigm Corporation, now associated with the Standard BioTools name. This summary reflects the filing provided, for the fiscal year ended December 31, 2015—not a standalone fourth-quarter filing.
Fluidigm developed and sold life-science instruments and consumables for single-cell genomics and proteomics, as well as production genomics. It reported approximately 1,630 systems sold worldwide by year-end. The DVS Sciences acquisition, completed in February 2014, expanded the business into mass cytometry and single-cell protein analysis.
Financial results and liquidity
| Metric | FY 2015 | FY 2014 |
|---|---|---|
| Total revenue | $114.7 million | $116.5 million |
| Product revenue | $102.1 million | $107.1 million |
| Service revenue | $12.3 million | $8.8 million |
| Operating loss | $50.2 million | $51.8 million |
| Net loss | $53.3 million | $52.8 million |
| Net loss per share | $1.86 | $1.90 |
| Cash used in operating activities | $34.7 million | $22.6 million |
- Product gross margin was 58%, down from 63%; service gross margin rose to 71% from 62%.
- Cash, cash equivalents, and short- and long-term investments totaled $101.5 million at December 31, 2015, down from $142.8 million a year earlier. Working capital, excluding deferred revenue, was $123.4 million.
- Convertible notes had a $201.3 million principal amount and a $195.7 million carrying value, net of discount. The notes bear 2.75% interest and mature in 2034, subject to conversion, redemption, and repurchase provisions.
- Total assets were $371.1 million and stockholders’ equity was $114.9 million. The company reported an accumulated deficit of $363.5 million.
- Fourth-quarter 2015 revenue was $30.7 million and net loss was $12.9 million.
Material changes versus prior periods
- FY 2015 revenue declined 1.5% year over year. Product revenue fell 5%, reflecting lower sales of core genomic systems and lower consumables volumes, partly offset by growth in Helios/CyTOF 2 and contributions from Juno and Polaris. Service revenue increased 40%, mainly from service contracts, installation, and training.
- Unfavorable foreign exchange, primarily the euro, reduced 2015 revenue by approximately $5.0 million, according to management.
- Product margin fell five percentage points, attributed to lower consumables capacity utilization, lower instrument selling prices, acquired-technology amortization, and higher IFC inventory reserves tied to product transitions.
- Operating loss narrowed modestly, but net loss remained broadly similar. Lower R&D expense and the $4.0 million escrow settlement gain were offset by higher selling, general and administrative expenses and interest expense.
- Operating cash use increased from $22.6 million to $34.7 million. Cash and investments fell by $41.3 million year over year.
Outlook, risks, and unusual items
- Management said existing cash, equivalents, and investments were expected to fund working-capital and capital-expenditure needs for at least 18 months. No numerical revenue or earnings guidance was provided; management said product revenue was expected to increase over time but gave no assurance of future growth.
- The company remained loss-making and stated it could continue to incur substantial losses and negative operating cash flow. Its ability to reach profitability was uncertain.
- A reported C1 IFC performance issue involved more than one cell in some chambers. The company was redesigning the IFCs and expected redesigned versions in the second quarter of 2016, subject to development and timing risks.
- Imaging Mass Cytometer products and additional Maxpar reagents were expected to become commercially available in the second half of 2016 or by year-end 2016, respectively.
- Key risks include intense competition and uncertain adoption of emerging single-cell markets; reliance on limited or sole-source suppliers; manufacturing concentration in Singapore and Canada; product defects and development delays; foreign-exchange exposure; and potential regulation of research-use-only products if used or promoted for diagnostic purposes.
- The Canadian proteomics manufacturing operation was being relocated to a larger facility, with potential for disruption. The company also planned FDA registration and selected 510(k) submissions; clearances and timing were not assured.
- The company purchased mass-cytometry patents from PerkinElmer for $6.5 million in November 2015. It recorded a $4.0 million gain when 170,107 DVS escrow shares were returned and canceled, and a $2.3 million Verinata milestone gain, collected in January 2016.
- Management and the auditor reported effective disclosure controls and internal control over financial reporting as of year-end. The filing said pending legal matters were not expected to have a material adverse effect, while noting litigation can still impose costs and management distraction.
Most important facts for investors to verify
- Confirm the issuer and ticker associated with this filing: the supplied document is Fluidigm Corporation’s 2015 Form 10-K, despite the request naming Standard BioTools Inc.
- Check subsequent results for revenue recovery, instrument sales, consumables pull-through, and whether the 2015 margin deterioration persisted.
- Verify actual operating cash burn and liquidity after year-end, including whether the stated 18-month funding expectation was met without additional financing.
- Review the notes’ conversion, repurchase, and redemption terms alongside the company’s ability to meet cash obligations.
- Confirm whether the C1 IFC redesign and announced product launches occurred on schedule and achieved customer acceptance.
- Assess the effects of foreign exchange, the Canadian facility relocation, supplier concentration, and any changes in FDA or laboratory-developed-test regulation.